Morgan Stanley
EVMN

Morgan Stanley’s Evommune Inc EVMN Stock Holding History

Morgan Stanley’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$576K Buy
25,070
+16,724
+200% +$378K ﹤0.01% 5421
2025
Q4 		$143K Buy
+8,346
New +$157K ﹤0.01% 6056

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Morgan Stanley's EVMN Position: Q1 2026 in Review

Morgan Stanley increased its Evommune Inc (EVMN) stake by 200% in Q1 2026, buying an estimated $378K and bringing the position to 25,070 shares worth $576K. The position accounts for ﹤0.01% of the portfolio, ranked #5421.

Morgan Stanley first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • Morgan Stanley held 25,070 shares of Evommune Inc worth $576K as of Q1 2026.
  • Morgan Stanley bought 16,724 Evommune Inc shares in Q1 2026, an estimated $378K.
  • Evommune Inc made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5421 holding.
  • Morgan Stanley first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.